TY - JOUR
AU1 - Kelderman, Sander
AU2 - Heemskerk, Bianca
AU3 - Tinteren, Harm
AU4 - Brom, Rob
AU5 - Hospers, Geke
AU6 - Eertwegh, Alfonsus
AU7 - Kapiteijn, Ellen
AU8 - Groot, Jan
AU9 - Soetekouw, Patricia
AU1 - Jansen, Rob
AU1 - Fiets, Edward
AU1 - Furness, Andrew
AU1 - Renn, Alexandra
AU1 - Krzystanek, Marcin
AU1 - Szallasi, Zoltan
AU1 - Lorigan, Paul
AU1 - Gore, Martin
AU1 - Schumacher, Ton
AU1 - Haanen, John
AU2 - Larkin, James
AU2 - Blank, Christian
AB - Cancer Immunol Immunother (2014) 63:449–458 DOI 10.1007/s00262-014-1528-9 OrIgInal artICle Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma Sander Kelderman · Bianca Heemskerk · Harm van Tinteren · Rob R. H. van den Brom · Geke A. P. Hospers · Alfonsus J. M. van den Eertwegh · Ellen W. Kapiteijn · Jan Willem B. de Groot · Patricia Soetekouw · Rob L. Jansen · Edward Fiets · Andrew J. S. Furness · Alexandra Renn · Marcin Krzystanek · Zoltan Szallasi · Paul Lorigan · Martin E. Gore · Ton N. M. Schumacher · John B. A. G. Haanen · James M. G. Larkin · Christian U. Blank received: 19 november 2013 / accepted: 22 February 2014 / Published online: 8 March 2014 © Springer-Verlag Berlin Heidelberg 2014 Abstract Methods Patients with advanced cutaneous melanoma Introduction Ipilimumab, a cytotoxic t lymphocyte- were treated in the netherlands (nl) and the United King- associated antigen-4 blocking antibody, has improved over- dom (UK) with ipilimumab at 3 mg/kg. Baseline charac- all survival (OS) in metastatic melanoma in phase III tri- teristics and peripheral blood parameters were assessed, als. However, about 80 % of patients fail to respond, and and patients 
TI - Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
JF - Cancer Immunology Immunotherapy
DO - 10.1007/s00262-014-1528-9
DA - 2014-03-08
UR - https://www.deepdyve.com/lp/springer-journals/lactate-dehydrogenase-as-a-selection-criterion-for-ipilimumab-rvIIt4bBay
SP - 449
EP - 458
VL - 63
IS - 5
DP - DeepDyve
ER -